BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38664644)

  • 1. CHOP regulated by METTL14-m6A affects cell cycle arrest and regorafenib sensitivity in HCC cells.
    Pan Y; You B; Zhao X; Zhang S; Li W
    BMC Cancer; 2024 Apr; 24(1):525. PubMed ID: 38664644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor Effect of Regorafenib on MicroRNA Expression in Hepatocellular Carcinoma Cell Lines.
    Takuma K; Fujihara S; Fujita K; Iwama H; Nakahara M; Oura K; Tadokoro T; Mimura S; Tani J; Shi T; Morishita A; Kobara H; Himoto T; Masaki T
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pin1 inhibition reverses the acquired resistance of human hepatocellular carcinoma cells to Regorafenib via the Gli1/Snail/E-cadherin pathway.
    Wang J; Zhang N; Han Q; Lu W; Wang L; Yang D; Zheng M; Zhang Z; Liu H; Lee TH; Zhou XZ; Lu KP
    Cancer Lett; 2019 Mar; 444():82-93. PubMed ID: 30583078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of IL-6Rα by ATF3 enhances IL-6 mediated sorafenib and regorafenib resistance in hepatocellular carcinoma.
    Dai Z; Wang X; Peng R; Zhang B; Han Q; Lin J; Wang J; Lin J; Jiang M; Liu H; Lee TH; Lu KP; Zheng M
    Cancer Lett; 2022 Jan; 524():161-171. PubMed ID: 34687791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1.
    Chen Y; Peng C; Chen J; Chen D; Yang B; He B; Hu W; Zhang Y; Liu H; Dai L; Xie H; Zhou L; Wu J; Zheng S
    Mol Cancer; 2019 Aug; 18(1):127. PubMed ID: 31438961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regorafenib inhibits tumor progression through suppression of ERK/NF-κB activation in hepatocellular carcinoma bearing mice.
    Weng MC; Wang MH; Tsai JJ; Kuo YC; Liu YC; Hsu FT; Wang HE
    Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29535278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RAB27A-dependent release of exosomes by liver cancer stem cells induces Nanog expression in their differentiated progenies and confers regorafenib resistance.
    Huang H; Hou J; Liu K; Liu Q; Shen L; Liu B; Lu Q; Zhang N; Che L; Li J; Jiang S; Wang B; Wen Q; Hu L; Gao J
    J Gastroenterol Hepatol; 2021 Dec; 36(12):3429-3437. PubMed ID: 34258777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regorafenib inhibits migration, invasion, and vasculogenic mimicry of hepatocellular carcinoma via targeting ID1-mediated EMT.
    Zhang N; Zhang S; Wu W; Lu W; Jiang M; Zheng N; Huang J; Wang L; Liu H; Zheng M; Wang J
    Mol Carcinog; 2021 Feb; 60(2):151-163. PubMed ID: 33428809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. piRNA-14633 promotes cervical cancer cell malignancy in a METTL14-dependent m6A RNA methylation manner.
    Xie Q; Li Z; Luo X; Wang D; Zhou Y; Zhao J; Gao S; Yang Y; Fu W; Kong L; Sun T
    J Transl Med; 2022 Jan; 20(1):51. PubMed ID: 35093098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
    Tong M; Che N; Zhou L; Luk ST; Kau PW; Chai S; Ngan ES; Lo CM; Man K; Ding J; Lee TK; Ma S
    J Hepatol; 2018 Oct; 69(4):826-839. PubMed ID: 29885413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of METTL3 and METTL14 in hepatocellular carcinoma.
    Liu X; Qin J; Gao T; Li C; Chen X; Zeng K; Xu M; He B; Pan B; Xu X; Pan Y; Sun H; Xu T; Wang S
    Aging (Albany NY); 2020 Nov; 12(21):21638-21659. PubMed ID: 33159022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. METTL14-mediated N6-methyladenosine modification of SOX4 mRNA inhibits tumor metastasis in colorectal cancer.
    Chen X; Xu M; Xu X; Zeng K; Liu X; Pan B; Li C; Sun L; Qin J; Xu T; He B; Pan Y; Sun H; Wang S
    Mol Cancer; 2020 Jun; 19(1):106. PubMed ID: 32552762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. METTL14 decreases FTH1 mRNA stability via m6A methylation to promote sorafenib-induced ferroptosis of cervical cancer.
    Li L; Zeng J; He S; Yang Y; Wang C
    Cancer Biol Ther; 2024 Dec; 25(1):2349429. PubMed ID: 38738555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of three m6A-related mRNAs signature and risk score for the prognostication of hepatocellular carcinoma.
    Li Z; Li F; Peng Y; Fang J; Zhou J
    Cancer Med; 2020 Mar; 9(5):1877-1889. PubMed ID: 31943856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma.
    Tai WT; Chu PY; Shiau CW; Chen YL; Li YS; Hung MH; Chen LJ; Chen PL; Su JC; Lin PY; Yu HC; Chen KF
    Clin Cancer Res; 2014 Nov; 20(22):5768-76. PubMed ID: 25248379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The distinct responsiveness of cytokeratin 19-positive hepatocellular carcinoma to regorafenib.
    Zhuo J; Lu D; Lin Z; Yang X; Yang M; Wang J; Tao Y; Wen X; Li H; Lian Z; Cen B; Dong S; Wei X; Xie H; Zheng S; Shen Y; Xu X
    Cell Death Dis; 2021 Nov; 12(12):1084. PubMed ID: 34785656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HBXIP drives metabolic reprogramming in hepatocellular carcinoma cells via METTL3-mediated m6A modification of HIF-1α.
    Yang N; Wang T; Li Q; Han F; Wang Z; Zhu R; Zhou J
    J Cell Physiol; 2021 May; 236(5):3863-3880. PubMed ID: 33305825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin Enhances the Effect of Regorafenib and Inhibits Recurrence and Metastasis of Hepatic Carcinoma After Liver Resection via Regulating Expression of Hypoxia Inducible Factors 2α (HIF-2α) and 30 kDa HIV Tat-Interacting Protein (TIP30).
    Yang Q; Guo X; Yang L
    Med Sci Monit; 2018 Apr; 24():2225-2234. PubMed ID: 29654226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of cyclin E1 sensitizes hepatocellular carcinoma cells to regorafenib by mcl-1 suppression.
    Xu J; Huang F; Yao Z; Jia C; Xiong Z; Liang H; Lin N; Deng M
    Cell Commun Signal; 2019 Jul; 17(1):85. PubMed ID: 31349793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma.
    Shigeta K; Matsui A; Kikuchi H; Klein S; Mamessier E; Chen IX; Aoki S; Kitahara S; Inoue K; Shigeta A; Hato T; Ramjiawan RR; Staiculescu D; Zopf D; Fiebig L; Hobbs GS; Quaas A; Dima S; Popescu I; Huang P; Munn LL; Cobbold M; Goyal L; Zhu AX; Jain RK; Duda DG
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33234602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.